Therapeutic management of patients with advanced thymic malignancies: A review for clinicians
Authors:
Open Access
- 29 April 2025
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 204, 108554
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- LBA8 Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble studyAnnals of Oncology, 2024
- Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic CarcinomasClinical Lung Cancer, 2024
- 2188P First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trialAnnals of Oncology, 2023
- LBA98 Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trialAnnals of Oncology, 2023
- Thymic epithelial tumors: From biology to treatmentCancer Treatment Reviews, 2020
- The Role of Adjuvant Therapy in Advanced Thymic Carcinoma: A National Cancer Database AnalysisThe Annals of Thoracic Surgery, 2020
- Chemotherapy in NETs: When and howReviews in Endocrine and Metabolic Disorders, 2017
- Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database StudyCancer, 2015
- Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapyJournal of Cancer Research and Clinical Oncology, 2014
- Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinomaCancer, 2003